BVNRY:OTC-Bavarian Nordic A/S (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 11.30

Change

+0.74 (+7.01)%

Market Cap

USD 1.95B

Volume

666.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox and monkey pox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola; MVA-BN HPV that is in Phase I clinical trials to treat human papillomavirus; MVA-BN WEV, which is in Phase I clinical trials to treat equine encephalitis; and BN-Brachyury that is in Phase II clinical trials for the treatment of chordoma. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Hellerup, Denmark.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-0.25 (-0.35%)

USD164.25B 28.86 2.79
CSLLY CSL Limited

-0.21 (-0.20%)

USD95.19B 45.87 26.33
CMXHF CSL Limited

+2.00 (+0.96%)

USD93.22B 45.07 26.33
GNMSF Genmab A/S

+9.05 (+2.11%)

USD27.95B 119.74 3.08
UCBJF UCB SA

-1.27 (-1.19%)

USD20.27B 19.83 17.47
UCBJY UCB SA

+0.22 (+0.40%)

USD20.24B 19.82 17.47
SBMFF Sino Biopharmaceutical Limited

+0.03 (+2.72%)

USD18.30B 27.88 2.96
SBHMY Sino Biopharmaceutical Limited

+0.28 (+1.54%)

USD17.90B 27.58 2.96
PPTDF PeptiDream Inc

N/A

USD7.04B 260.99 1.65
AKABY ALK-Abelló A/S

N/A

USD5.61B 526.20 11.83

ETFs Containing BVNRY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.12% 44% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.12% 43% F 51% F
Trailing 12 Months  
Capital Gain 21.37% 51% F 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.37% 51% F 58% F
Trailing 5 Years  
Capital Gain -26.30% 51% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.30% 50% F 29% F
Average Annual (5 Year Horizon)  
Capital Gain 0.59% 40% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.59% 39% F 39% F
Risk Return Profile  
Volatility (Standard Deviation) 36.35% 73% C 51% F
Risk Adjusted Return 1.62% 39% F 38% F
Market Capitalization 1.95B 92% A- 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.09 57% F 54% F
Price/Book Ratio 2.16 78% C+ 43% F
Price / Cash Flow Ratio -7.08 59% F 78% C+
EV/EBITDA 1.57 75% C 61% D-
Management Effectiveness  
Return on Equity 16.95% 89% B+ 87% B+
Return on Invested Capital -10.23% 54% F 24% F
Return on Assets 7.32% 95% A 91% A-
Debt to Equity Ratio 21.20% 30% F 58% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.45 27% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector